Introduction: Intravitreal anti-VEGF is the most effective therapy for wet AMD, although systemic effects on the endothelium cannot be excluded. Areas covered: The purpose of this review was to evaluate risk of thromboembolic events associated with intravitreal anti-VEGF. Expert opinion: Current data are insufficient to confirm the safety of these compounds, due to the paucity of specific studies. Thus, pharmacovigilance for all anti-VEGF should be improved to verify the true role of anti-VEGF in the occurrence of systemic adverse events.

Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an update / Costagliola, Ciro; Morescalchi, Francesco; Duse, Sarah; Romano, Davide; Mazza, Giuseppina; Parmeggiani, Francesco; Bartollino, Silvia; Semeraro, Francesco. - In: EXPERT OPINION ON DRUG SAFETY. - ISSN 1474-0338. - (2019). [10.1080/14740338.2019.1643838]

Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an update

Costagliola, Ciro;
2019

Abstract

Introduction: Intravitreal anti-VEGF is the most effective therapy for wet AMD, although systemic effects on the endothelium cannot be excluded. Areas covered: The purpose of this review was to evaluate risk of thromboembolic events associated with intravitreal anti-VEGF. Expert opinion: Current data are insufficient to confirm the safety of these compounds, due to the paucity of specific studies. Thus, pharmacovigilance for all anti-VEGF should be improved to verify the true role of anti-VEGF in the occurrence of systemic adverse events.
2019
Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an update / Costagliola, Ciro; Morescalchi, Francesco; Duse, Sarah; Romano, Davide; Mazza, Giuseppina; Parmeggiani, Francesco; Bartollino, Silvia; Semeraro, Francesco. - In: EXPERT OPINION ON DRUG SAFETY. - ISSN 1474-0338. - (2019). [10.1080/14740338.2019.1643838]
File in questo prodotto:
File Dimensione Formato  
2019_Systemic thromboemolitic.pdf

non disponibili

Dimensione 552.94 kB
Formato Adobe PDF
552.94 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/871185
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 13
social impact